Actively Recruiting
Respiratory Dysbiosis in Preschool Children with Asthma: Predictive of a Severe Form
Led by University Hospital, Brest · Updated on 2024-09-23
30
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The prevalence of asthma in preschool children is between 11 and12%. Inhaled corticosteroid therapy is the main therapy used, however this treatment seems insufficiently effective in some children. Recent research in cystic fibrosis has made it possible to highlight pulmotypes corresponding to the different stages of pulmonary dysbiosis, and a predictive microbiological signature of an increased risk of early primocolonization to P. aeruginosa. These pulmotypes are the result of the so-called "enterotyping" analysis, a biostatistical method that makes it possible to stratify individuals according to the analysis of the microbiota. In the light of these data, it seems interesting to transcribe the concept of using a biomarker of the microbiota in the monitoring of a chronic lung disease such as asthma. The hypothesis is that there is respiratory dysbiosis causing corticosteroid resistance to treatment in children under 3 years of age with severe asthma.
CONDITIONS
Official Title
Respiratory Dysbiosis in Preschool Children with Asthma: Predictive of a Severe Form
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than 1 year and less than 3 years
- Diagnosis of asthma by a pediatrician
- Parental consent
- Affiliation to the social security system
You will not qualify if you...
- Chronic pathologies: congenital heart disease, immune deficiency, cystic fibrosis, bronchopulmonary dysplasia, encephalopathy, primary ciliary dyskinesia, laryngomalacia, digestive pathology requiring digestive surgery
- Premature birth before 34 weeks of gestation
- Antibiotic therapy within the past 7 days
- Oral corticosteroid treatment within the previous 10 days
- Patient whose parent(s) is (are) minor(s)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Brest
Brest, Finistère, France, 29609
Actively Recruiting
Research Team
P
Pierrick CROS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here